Regent Assay advises DTR Medical on its acquisition by Innovia Medical

Regent Assay is pleased to announce it acted as the exclusive corporate finance advisor to the shareholders of DTR Medical Ltd (‘DTR Medical’ or the ‘Company’) on its acquisition by US manufacturer Innovia Medical.

Based in Wales, United Kingdom, DTR Medical is a multi-award winning manufacturer of quality and innovative single-use instruments. The Company sells its diverse range of sterile surgical instruments and medical consumables to over 30 countries, 400 NHS surgical centres and most Private groups operating in the UK. Flagship products include the Rotating Biopsy Punch, Frazier Suction Handle, Tibbs Arterial Cannula and Ear Specula.

Innovia Medical, backed by Shore Capital Partners, is a family of specialty surgical companies that are passionately committed to partnering with medical professionals to help elevate the delivery of patient care and improve clinical outcomes. Innovia Medical companies include Summit Medical, Shippert Medical, Network Medical.

Terry Meredith (Chief Executive of Innovia Medical) stated “The strategic acquisition of DTR Medical will further strengthen Innovia’s global position in the ENT and Ophthalmic market; in addition, providing new opportunities in areas such as Gynaecology and General Surgery.”

Richard Salvage (Chairman and Founder of DTR Medical) commented on Regent Assay’s role in the transaction: “The Regent Assay team led by Ian Bussey provided us with expert guidance throughout the sale process. We initially engaged with them in mid 2018 prior to our planned exit as part of their Equity Acceleration Programme, which not only helped us to focus on key areas of value creation but ensured we managed out any risks in our business prior to sale. This strategic advice was an invaluable service and helped us to prepare in a timely manner the business for an optimum sale. We would not hesitate to recommend them for any corporate finance advice and we look forward to the next phase of the DTR journey.”

Andrew Davidson (Managing Director of DTR Medical) continued, “We are excited to be partnering with Innovia Medical as this investment will allow us to continue to develop our innovative surgical solutions, whilst bringing our products to a wider global audience.”

Regent Assay initiated discussions and negotiations in a process that ultimately resulted in a successful transaction with Innovia Medical. The transaction highlights Regent Assay’s deep expertise in the Healthcare sector, following transactions with CooperSurgical, National Slimming & Cosmetic Companies and Reed Shilling Healthcare.